导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 26.20% | 174/3712 |
| 近一周 | 0.59% | 440/4228 |
| 近一月 | -5.72% | 2965/4196 |
| 近一季 | -13.70% | 3210/4044 |
| 近半年 | 23.00% | 120/3824 |
| 近一年 | 28.78% | 213/3446 |
| 近两年 | 164.33% | 140/2399 |
| 近三年 | 137.89% | 30/1802 |
| 成立以来 | 33.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.10% 4211/4961 |
89.35% 131/5312 |
- - |
- - |
| 2025 | 45.64% 608/4813 |
-0.61% 2325/3635 |
-0.47% 2932/4076 |
57.72% 155/4524 |
-6.66% 3725/4813 |
| 2024 | 29.18% 135/3463 |
-3.76% 1557/2808 |
4.41% 215/3014 |
13.99% 2063/3129 |
12.77% 170/3463 |
| 2023 | 3.63% 269/2656 |
17.13% 176/2280 |
-3.77% 893/2385 |
-7.88% 1636/2515 |
-0.20% 189/2655 |
| 2022 | -37.34% 1753/2207 |
-24.51% 1769/1919 |
-0.25% 1605/2016 |
-19.39% 1776/2113 |
3.21% 747/2208 |
| 2021 | 7.26% 501/1822 |
-11.15% 1129/1255 |
22.49% 123/1330 |
-10.10% 1209/1466 |
9.63% 115/1822 |
| 2020 | - - |
- - |
- - |
- - |
6.32% 762/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝中证电子50ETF VS. 长安沪深300非周期A(740101) |